NEW YORK, NY - April 1, 2014 - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company developing genomic-based oncology tests and services to enhance disease management and patient outcomes. The Company offers a wide-range of proprietary and non-proprietary tests to support patients during all aspects of their care, from initial diagnosis to prognosis, and determination of optimal treatment options. Oncology is moving towards categorizing cancers by their molecular signature rather than the location in the body, and there is a continuing need for wider access to diagnostic toolkits. Cancer Genetics collaborates with leading research institutions for biomarker development, with community hospitals to improve patient care, and with biotechnology and pharmaceutical companies to provide clinical trial services.
"Cancer Genetics couples its expertise identifying genetic aberrations with recommendations for patient prognosis and treatment, generating a personalized therapeutic plan for each patient," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "This level of focus on the patient has led to key partnerships with Gilead and Roche, and sets the stage for continued integration into the pursuit of personalized medicine in oncology."
Cancer Genetics has five unique tests that are approved by New York State and Clinical Laboratory Improvement Amendments (CLIA) for leukemia, lymphomas, renal and cervical cancer. Mature B-cell Neoplasm Array (MatBA®) is a genomic hybridization array for the diagnosis and prognosis of non-Hodgkin lymphomas. UroGenRA™ is a genomic hybridization array for the classification of urogenital cancers, and FISH-based HPV-Associated Cancer Test (FHACT™) is a platform for HPV-associated cervical cancer screening. Additional indications are being pursued for each platform.
Cancer Genetics has deals in place with Gilead Sciences, Inc. and Roche Servicios S.A., a Costa Rica-based subsidiary of Roche. The partnerships are a validation of the Cancer Genetics' ability to secure the necessary relationships to become the market leader in diagnostics. Additionally, Cancer Genetics continues to invest in developing further technology by leveraging next-generation sequencing in a joint venture with Mayo Clinic that is focused on developing panels for oncology indications in lung cancer, follicular lymphoma, and multiple myeloma.
In a 35 page Initiation Report by LifeSci Advisors, we explain the products and services offered by Cancer Genetics and how the Company intends to continue expanding revenues. The report discusses the three proprietary technology platforms and the indications they target. We also explore the market potential and competitive landscape for molecular diagnostics going forward.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
SOURCE: LifeSci Advisors